Experience with the drug 5 % human normal immunoglobulin for intravenous administration of Ig Vena N.I.V. in the treatment of immune thrombocytopenic purpura in children
https://doi.org/10.17650/2311-1267-2016-3-3-52-58
Abstract
Intravenous immunoglobulin (IVIG) is the first-line therapy for immune thrombocytopenia (ITP) at children. However, IVIGs are not absolutely comparable, as routine practice shows, so the choice of IVIG requires analysis of specific clinical cases and studies. IVIGs application requires to take into account not only effectiveness, but also tolerability. We investigated effectiveness and safety of Ig VENA (Kedrion S.p.A., Italy) administration for treatment of 62 patients with initially diagnosed ITP at the age of 6 months to 15 years. Positive effect of application of the medication reached at 85.5 % of children with this disease. None of the patients experienced serious adverse events during the study period. Short-term adverse events (fever, nausea, headache) were registered at 16.1 % of patients and did not require discontinuation of Ig VENA therapy. Thus, our study demonstrated the high effectiveness and safety of Ig VENA therapy for children with ITP.
About the Authors
V. Yu. Petrov
Morozov Children’s Hospital
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
E. V. Ageenkova
Morozov Children’s Hospital
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
E. A. Yatsenko
Morozov Children’s Hospital
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
I. N. Lavrentieva
Morozov Children’s Hospital
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
A. A. Kazankova
Morozov Children’s Hospital
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
L. E. Larina
Morozov Children’s Hospital
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
K. L. Kondratchik
Morozov Children’s Hospital
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
I. E. Koltunov
Morozov Children’s Hospital
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
Russian Federation
1/9 4th Dobryninskiy Per., Moscow, 119049
References
1. Петров В.Ю., Сосков Г.И., Плахута Т.Г., Агеенкова Э.В. Современные представления о патофизиологии и терапии идиопатической тромбоцитопенической пурпуры. Педиатрия 2009;88(4):125–34. [Petrov V.Yu., Soskov G.I., Plakhuta T.G., Ageenkova E.V. Modern understanding of the pathophysiology and treatment of idiopathic thrombocytopenic purpura. Pediatriya = Pediatrics 2009;88(4):125–34. (In Russ.)].
2. Harrington W.J., Minnich V., Hollingsworth J.W., Moore C.V. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38(1):1 –10.
3. Shulman N.R., Marder V.J., Weinrach R.S. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopicstudies. Ann N Y Acad Sci 1965;124(2):499–542.
4. van Leeuwen E.F., van der Ven J.T., Engelfriet C.P., von dem Borne A.E. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood 1982;59(1):23–6.
5. McMillan R., Wang L., Tani P. Prospective evaluation of the immunobead assay for the diagnosis adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003;1(3):485–91.
6. Brighton T.A., Evans S., Castaldi P.A. et al. Prospective evaluation of the clinical usefulness of an antigenspecific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996;88(1):194–201.
7. Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 2002;346(13):995–1008.
8. Петров В.Ю. Современные аспекты этиопатогенеза, клинического течения и терапии острой тромбоцитопенической пурпуры у детей. Автореф. дис. … д-ра мед. наук. М., 2005. 43 с. [Petrov V.Yu. Modern aspects of etiology and pathogenesis, clinical course and treatment of acute thrombocytopenic purpura in children. Thesis abstract of … Ph. D. Med. Moscow, 2005. 43 р. (In Russ.)].
9. Lazarus A.H., Crow A.R. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003;28(3):249–55.
10. Kattamis A.C., Shankar S., Cohen A.R. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr 1997;130(2):281–3.
11. Summary of product characteristics. Available at: http://www.biogenetech.co.th/wpcontent/uploads/2011/10/IgVena_PI0605_E1002_rev.01.pdf.
Review
For citations:
Petrov V.Yu., Ageenkova E.V., Yatsenko E.A., Lavrentieva I.N., Kazankova A.A., Larina L.E., Kondratchik K.L., Koltunov I.E. Experience with the drug 5 % human normal immunoglobulin for intravenous administration of Ig Vena N.I.V. in the treatment of immune thrombocytopenic purpura in children. Russian Journal of Pediatric Hematology and Oncology. 2016;3(3):52-58. (In Russ.) https://doi.org/10.17650/2311-1267-2016-3-3-52-58
Views:
1253
Email this article 